TNFRSF17 and Miyoshi myopathy: Besides anti-BCMA CAR-T cell therapy, anti-CD138, targeting κ light chains, or anti-NKG2D CAR-T therapy did not achieve an ideal efficacy in causing remission of R/R MM [15] [16] [17].